Drug Safety

, Volume 36, Issue 8, pp 663–671 | Cite as

Profile of Sexual and Genitourinary Treatment-Emergent Adverse Events Associated with Atomoxetine Treatment: A Pooled Analysis

  • Angelo Camporeale
  • Kathleen Ann Day
  • Dustin Ruff
  • Jody Arsenault
  • David Williams
  • Douglas K. Kelsey
Original Research Article



Attention-deficit hyperactivity disorder (ADHD) is a neuropsychiatric disorder that begins in childhood. Atomoxetine is a selective inhibitor of the presynaptic norepinephrine transporter. Several studies have demonstrated the safety and efficacy of atomoxetine in the treatment of ADHD.


The objective of this analysis was to provide additional information on the frequency, time to onset and time to resolution of sexual and genitourinary (GU) treatment-emergent adverse events (TEAEs) reported during atomoxetine treatment in clinical trials.


Data from all adult atomoxetine placebo-controlled ADHD trials were pooled for this analysis, for a total of 3,314 patients (atomoxetine, n = 1,738; placebo, n = 1,576). Additionally, data from all adolescent patients (baseline age ≥13 to <18 years) within all ADHD placebo-controlled trials were pooled for analysis, for a total of 538 patients (atomoxetine, n = 329; placebo, n = 209). Rates of sexual and GU TEAEs were summarized by sex for each age group. Time to onset and resolution of sexual and GU TEAEs were summarized and compared using Kaplan–Meier methods.


Overall, the baseline characteristics of randomized patients in the atomoxetine and placebo groups were similar. Profiles of sexual and GU TEAEs for atomoxetine appeared clinically similar to placebo in female patients and in adolescent male patients. Adult male patients reported relatively more sexual and GU TEAEs when taking atomoxetine compared with placebo, with libido decreased (4.6 vs. 3.0 %), dysuria (3.7 vs. 1.5 %), urinary hesitation (6.9 vs. 2.4 %), urine flow decreased (2.5 vs. 0.6 %), ejaculation disorder (2.8 vs. 1.1 %) and erectile dysfunction (8.0 vs. 1.9 %) being the most common. The time to onset of the most common TEAEs in adult male patients tended to occur relatively early in dosing: within the first 2 weeks for GU TEAEs, and during the second and third week of dosing for erectile and ejaculation issues. The median time to resolution for these events ranged from around 3–8 weeks after event onset, depending on the event. While the common sexual and GU TEAEs showed numerically higher percentages of discontinuations in atomoxetine-treated patients compared with placebo, most incidences of the sexual and GU TEAEs were not considered severe.


The sexual and GU TEAE profiles of patients taking atomoxetine were generally similar to those of patients taking placebo in the female and adolescent male populations, with greater frequency of TEAEs reported in adult males taking atomoxetine compared with placebo. The time to onset of the TEAEs tended to be shorter, and time to resolution tended to be longer in adult male patients treated with atomoxetine compared with those receiving placebo. The conclusions must be interpreted with caution because the TEAEs were likely underreported.

Supplementary material

40264_2013_74_MOESM1_ESM.pdf (170 kb)
Supplementary material 1 (PDF 169 kb)


  1. 1.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed, text revision. Washington, DC: American Psychiatric Press; 2000.Google Scholar
  2. 2.
    Wender PH, Wolf LE, Wasserstein J. Adults with ADHD: an overview. Ann N Y Acad Sci. 2001;931:1–16.CrossRefPubMedGoogle Scholar
  3. 3.
    Wilens TE, Dodson W. A clinical perspective of attention-deficit/hyperactivity disorder into adulthood. J Clin Psychiatry. 2004;65(10):1301–13.CrossRefPubMedGoogle Scholar
  4. 4.
    Kessler RC, Coccaro EF, Fava M, et al. The prevalence and correlates of DSM-IV intermittent explosive disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2006;63(6):669–78.CrossRefPubMedGoogle Scholar
  5. 5.
    Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007;190:402–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716–23.CrossRefPubMedGoogle Scholar
  7. 7.
    Barkley RA. Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63(Suppl. 12):10–5.PubMedGoogle Scholar
  8. 8.
    Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108(5):E83.CrossRefPubMedGoogle Scholar
  9. 9.
    Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159(11):1896–901.CrossRefPubMedGoogle Scholar
  10. 10.
    Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology. 2005;65(12):1941–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics. 2004;114(1):e1–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53(2):112–20.CrossRefPubMedGoogle Scholar
  13. 13.
    Adler LA, Spencer T, Brown TE, et al. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol. 2009;29(1):44–50.CrossRefPubMedGoogle Scholar
  14. 14.
    Young JL, Sarkis E, Qiao M, et al. Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol. 2011;34(2):51–60.PubMedGoogle Scholar
  15. 15.
    Durell T, Adler L, Wilens T, et al. Atomoxetine treatment for ADHD: younger adults compared with older adults. J Atten Disord. 2010;13(4):401–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Wietecha LA, Williams DW, Herbert M, et al. Atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(6):719–30.CrossRefPubMedGoogle Scholar
  17. 17.
    Adler LA, Liebowitz M, Kronenberger W, et al. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety. 2009;26(3):212–21.CrossRefPubMedGoogle Scholar
  18. 18.
    Strattera® (atomoxetine). US prescribing information. Indianapolis: Eli Lilly and Company; 2011.Google Scholar
  19. 19.
    Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27(5):699–711.CrossRefPubMedGoogle Scholar
  20. 20.
    Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. 1993;52(12):1023–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Tatsumi M, Groshan K, Blakely RD, et al. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997;340(2–3):249–58.CrossRefPubMedGoogle Scholar
  22. 22.
    Gehlert DR, Schober DA, Gackenheimer SL. Comparison of (R)-[3H]tomoxetine and (R/S)-[3H]nisoxetine binding in rat brain. J Neurochem. 1995;64(6):2792–800.CrossRefPubMedGoogle Scholar
  23. 23.
    Wong DT, Threlkeld PG, Best KL, et al. A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J Pharmacol Exp Ther. 1982;222(1):61–5.PubMedGoogle Scholar
  24. 24.
    Wilens TE. Mechanism of action of agents used in attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2006;67(Suppl. 8):32–8.PubMedGoogle Scholar
  25. 25.
    Sumner CR, Schuh KJ, Sutton VK, et al. Placebo-controlled study of the effects of atomoxetine on bladder control in children with nocturnal enuresis. J Child Adolesc Psychopharmacol. 2006;16(6):699–711.CrossRefPubMedGoogle Scholar
  26. 26.
    Viktrup L, Pangallo BA, Detke MJ, et al. Urinary side effects of duloxetine in the treatment of depression and stress urinary incontinence. Prim Care Companion J Clin Psychiatry. 2004;6(2):65–73.CrossRefPubMedGoogle Scholar
  27. 27.
    Scharko AM. Selective serotonin reuptake inhibitor-induced sexual dysfunction in adolescents: a review. J Am Acad Child Adolesc Psychiatry. 2004;43(9):1071–9.CrossRefPubMedGoogle Scholar
  28. 28.
    CONCERTA® (methylphenidate HCl) extended-release tablets CII. US prescribing information. Titusville: Ortho-McNeil-Janssen Pharmaceuticals; 2010.Google Scholar
  29. 29.
    Vyvanse (lisdexamfetamine dimesylate) capsule. US prescribing information. Wayne: Shire LLC; 2012.Google Scholar
  30. 30.
    Adderall (dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate) tablet. US prescribing information. Wayne: Shire US Inc.; 2006.Google Scholar
  31. 31.
    Edronax (reboxetine) 4 mg tablets: summary of product characteristics. Kent: Pharmacia Limited; 2011.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Angelo Camporeale
    • 1
  • Kathleen Ann Day
    • 1
  • Dustin Ruff
    • 1
  • Jody Arsenault
    • 2
  • David Williams
    • 2
  • Douglas K. Kelsey
    • 1
  1. 1.Lilly Research LaboratoriesEli Lilly and CompanyIndianapolisUSA
  2. 2.inVentiv Health ClinicalIndianapolisUSA

Personalised recommendations